Merck & Co., Inc. (Merck), a leading pharmaceutical company, filed an amendment to its annual report on Form 10-K/A with the Securities and Exchange Commission on April 11, 2024. This amendment was made to correct the date of the upcoming Annual Meeting of Shareholders, which was previously stated as May 18, 2024, but is actually scheduled for May 28, 2024. The amendment includes changes to Part III, Items 10 through 14, and the cover of the filing, as well as new certifications from the principal executive officer and principal financial officer. The company has confirmed that this amendment does not reflect any events occurring after the original filing or modify any other disclosures, except for the correction of the shareholder meeting date. Merck has also filed all required...Show More

Merck & Co., Inc. (Merck), a leading pharmaceutical company, filed an amendment to its annual report on Form 10-K/A with the Securities and Exchange Commission on April 11, 2024. This amendment was made to correct the date of the upcoming Annual Meeting of Shareholders, which was previously stated as May 18, 2024, but is actually scheduled for May 28, 2024. The amendment includes changes to Part III, Items 10 through 14, and the cover of the filing, as well as new certifications from the principal executive officer and principal financial officer. The company has confirmed that this amendment does not reflect any events occurring after the original filing or modify any other disclosures, except for the correction of the shareholder meeting date. Merck has also filed all required reports within the preceding 12 months and has been subject to filing requirements for the past 90 days. The company is identified as a large accelerated filer and has submitted all necessary Interactive Data Files. As of January 31, 2024, Merck had 2,532,643,872 shares of common stock outstanding, with an aggregate market value held by non-affiliates of approximately $292.9 billion as of June 30, 2023. The company's common stock is registered on the New York Stock Exchange under the symbol MRK, along with several notes due between 2024 and 2036. The filing also references various documents incorporated by reference, including the company's Code of Conduct and information on executive compensation, director compensation, and equity compensation plans.